ZA200800640B - Liquid formulations - Google Patents

Liquid formulations

Info

Publication number: ZA200800640B
Authority: ZA; South Africa
Prior art keywords: liquid formulations; formulations; liquid
Prior art date: 2005-08-09

Application number

ZA200800640A

Other languages

English (en)

Inventor

Georgousis Vivian

Tong Wei-Qin

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-08-09

Filing date

2008-01-22

Publication date

2008-12-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37734410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200800640(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-01-22 Application filed by Novartis Ag filed Critical Novartis Ag

2008-12-31 Publication of ZA200800640B publication Critical patent/ZA200800640B/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/141—Esters of phosphorous acids

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Biochemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Transplantation (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)

ZA200800640A 2005-08-09 2008-01-22 Liquid formulations ZA200800640B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US70682005P	2005-08-09	2005-08-09

Publications (1)

Publication Number	Publication Date
ZA200800640B true ZA200800640B (en)	2008-12-31

Family

ID=37734410

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200800640A ZA200800640B (en)	2005-08-09	2008-01-22	Liquid formulations

Country Status (23)

Country	Link
US (4)	US20080194526A1 (es)
EP (1)	EP1915130B1 (es)
JP (1)	JP5068755B2 (es)
KR (1)	KR101473494B1 (es)
CN (1)	CN101237852B (es)
AR (1)	AR056020A1 (es)
AU (1)	AU2006280138B2 (es)
BR (1)	BRPI0615009A2 (es)
CA (1)	CA2618018C (es)
EC (1)	ECSP088165A (es)
GT (1)	GT200600350A (es)
IL (1)	IL188915A0 (es)
MA (1)	MA29736B1 (es)
MX (1)	MX2008001967A (es)
MY (1)	MY145111A (es)
NO (1)	NO20081218L (es)
NZ (2)	NZ565696A (es)
PE (2)	PE20100149A1 (es)
RU (2)	RU2428180C2 (es)
TN (1)	TNSN08061A1 (es)
TW (1)	TWI317289B (es)
WO (1)	WO2007021666A2 (es)
ZA (1)	ZA200800640B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20130041385A (ko) *	2004-11-29	2013-04-24	노파르티스 아게	Ｓ１ｐ 수용체 효능제의 투여 용법
NZ568068A (en)	2005-11-09	2011-10-28	Proteolix Inc	Compounds for enzyme inhibition
SI2041158T1 (sl)	2006-06-19	2013-09-30	Onyx Therapeutics, Inc.	Peptidni epoksiketoni za inhibicijo proteasomov
AU2008307510A1 (en)	2007-10-04	2009-04-09	Onyx Therapeutics, Inc.	Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
CA2925175A1 (en) *	2007-10-12	2009-04-16	Novartis Ag	Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
WO2009155475A1 (en) *	2008-06-20	2009-12-23	Novartis Ag	Paediatric compositions for treating1 multiple sclerosis
US20110236428A1 (en)	2008-10-21	2011-09-29	Onyx Therapeutics, Inc.	Combination therapy with peptide epoxyketones
US8680146B2 (en)	2008-11-11	2014-03-25	Novartis Ag	Organic compounds
RU2011129230A (ru)	2008-12-18	2013-01-27	Новартис Аг	Новая полиморфная форма 1-[4-[1-(4-циклогексил-3-трифторметилбензилоксиимино)этил]-2-этилбензил]азетидин-3-карбоновой кислоты
CN103204794A (zh)	2008-12-18	2013-07-17	诺瓦提斯公司	新的盐
JP5627597B2 (ja) *	2008-12-18	2014-11-19	ノバルティスアーゲー	１−［４−［１−（４−シクロヘキシル−３−トリフルオロメチル−ベンジルオキシイミノ）−エチル］−２−エチル−ベンジル］−アゼチジン−３−カルボン酸ヘミフマル酸塩
PT2400960E (pt) *	2009-02-24	2013-06-28	Novartis Ag	Metabolitos análogos à ceramida
US20100243087A1 (en) *	2009-03-03	2010-09-30	Millipore Corporation	System and pump apparatus for processing fluid samples
TWI504598B (zh)	2009-03-20	2015-10-21	Onyx Therapeutics Inc	結晶性三肽環氧酮蛋白酶抑制劑
WO2011060179A1 (en)	2009-11-13	2011-05-19	Onyx Therapeutics, Inc	Use of peptide epoxyketones for metastasis suppression
US9359398B2 (en)	2010-03-01	2016-06-07	Onyx Therapeutics, Inc.	Compounds for immunoproteasome inhibition
ES2751920T3 (es)	2011-01-07	2020-04-02	Novartis Ag	Formulaciones inmunosupresoras
WO2012095853A1 (en)	2011-01-10	2012-07-19	Novartis Pharma Ag	Modified release formulations comprising sip receptor modulators
JO3177B1 (ar)	2011-04-01	2018-03-08	Novartis Ag	تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
TW201414751A (zh)	2012-07-09	2014-04-16	歐尼克斯治療公司	肽環氧酮蛋白酶抑制劑之前驅藥物
RU2496486C1 (ru)	2012-07-11	2013-10-27	Александр Васильевич Иващенко	Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
MX2016001422A (es)	2013-07-29	2016-10-05	Aizant Drug Res Solutions Pvt Ltd	Composicion farmaceutica de fingolimod.
WO2016042493A1 (en)	2014-09-19	2016-03-24	Aizant Drug Research Pvt. Ltd	Pharmaceutical compositions of fingolimod
CA2973540A1 (en)	2015-02-26	2016-09-01	Novartis Ag	Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
US11434200B2 (en)	2017-03-09	2022-09-06	Novartis Ag	Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
US11629124B2 (en)	2017-03-09	2023-04-18	Novartis Ag	Solid forms comprising an oxime ether compound, compositions and methods of use thereof
KR20200059221A (ko)	2017-09-27	2020-05-28	노파르티스 아게	시포니모드를 포함하는 비경구 제형
US20200306222A1 (en)	2017-09-29	2020-10-01	Novartis Ag	Dosing Regimen of Siponimod
AU2018341154A1 (en)	2017-09-29	2020-03-12	Novartis Ag	Dosing regimen of siponimod
WO2021214717A1 (en)	2020-04-23	2021-10-28	Novartis Ag	Dosing regimen for the use of siponimod for the treatment of acute respiratory distress syndrome

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2126658T3 (es) *	1992-10-21	1999-04-01	Yoshitomi Pharmaceutical	Compuesto de 2-amino-1,3-propanodiol e inmunosupresor.
DE19645549A1 (de) *	1996-11-05	1998-05-07	Bayer Ag	Verfahren zur Herstellung von 2-Methyl-2,4-diaminopentan
CA2286315C (en) *	1997-04-04	2007-03-06	Yoshitomi Pharmaceutical Industries Ltd.	2-aminopropane-1,3-diol compound, pharmaceutical use thereof and synthetic intermediates therefor
US6727283B2 (en) *	1998-10-13	2004-04-27	Pfizer Inc.	Sertraline oral concentrate
JP4627356B2 (ja) *	1999-06-30	2011-02-09	昭松森	ウイルス性心筋炎の予防または治療薬剤
US20040235794A1 (en) *	2001-09-04	2004-11-25	Shinji Nakade	Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller
DE60235900D1 (de) *	2001-09-27	2010-05-20	Kyorin Seiyaku Kk	Osuppressivum
CN1329372C (zh) *	2001-09-27	2007-08-01	杏林制药株式会社	二芳基硫醚衍生物及其加成盐和免疫抑制剂
US20040058894A1 (en) *	2002-01-18	2004-03-25	Doherty George A.	Selective S1P1/Edg1 receptor agonists
SI1505959T1 (sl) *	2002-05-16	2009-04-30	Novartis Ag	Uporaba vezavnih sredstev EDG receptorjev pri raku
CA2539438A1 (en) *	2003-10-01	2005-04-14	Merck And Co., Inc.	3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists

2006
- 2006-08-04 GT GT200600350A patent/GT200600350A/es unknown
- 2006-08-07 AR ARP060103432A patent/AR056020A1/es unknown
- 2006-08-07 PE PE2009001335A patent/PE20100149A1/es not_active Application Discontinuation
- 2006-08-07 PE PE2006000957A patent/PE20070337A1/es not_active Application Discontinuation
- 2006-08-08 BR BRPI0615009-8A patent/BRPI0615009A2/pt not_active IP Right Cessation
- 2006-08-08 CA CA2618018A patent/CA2618018C/en not_active Expired - Fee Related
- 2006-08-08 RU RU2008108887/15A patent/RU2428180C2/ru not_active IP Right Cessation
- 2006-08-08 MY MYPI20063826A patent/MY145111A/en unknown
- 2006-08-08 TW TW095129275A patent/TWI317289B/zh not_active IP Right Cessation
- 2006-08-08 RU RU2011106364/15A patent/RU2470631C2/ru not_active IP Right Cessation
- 2006-08-08 CN CN2006800286163A patent/CN101237852B/zh not_active Expired - Fee Related
- 2006-08-08 NZ NZ565696A patent/NZ565696A/en not_active IP Right Cessation
- 2006-08-08 AU AU2006280138A patent/AU2006280138B2/en not_active Ceased
- 2006-08-08 MX MX2008001967A patent/MX2008001967A/es active IP Right Grant
- 2006-08-08 WO PCT/US2006/030836 patent/WO2007021666A2/en active Application Filing
- 2006-08-08 EP EP06800936.4A patent/EP1915130B1/en active Active
- 2006-08-08 US US11/997,909 patent/US20080194526A1/en not_active Abandoned
- 2006-08-08 JP JP2008526120A patent/JP5068755B2/ja not_active Expired - Fee Related
- 2006-08-08 NZ NZ593121A patent/NZ593121A/xx not_active IP Right Cessation
2008
- 2008-01-21 IL IL188915A patent/IL188915A0/en unknown
- 2008-01-22 ZA ZA200800640A patent/ZA200800640B/xx unknown
- 2008-02-05 KR KR1020087003142A patent/KR101473494B1/ko not_active Expired - Fee Related
- 2008-02-08 TN TNP2008000061A patent/TNSN08061A1/en unknown
- 2008-02-08 MA MA30632A patent/MA29736B1/fr unknown
- 2008-02-08 EC EC2008008165A patent/ECSP088165A/es unknown
- 2008-03-07 NO NO20081218A patent/NO20081218L/no not_active Application Discontinuation
2012
- 2012-09-07 US US13/606,118 patent/US20120328664A1/en not_active Abandoned
2013
- 2013-12-06 US US14/099,072 patent/US20150080347A9/en not_active Abandoned
2015
- 2015-10-15 US US14/883,729 patent/US20160030572A1/en not_active Abandoned

Also Published As

Publication number	Publication date
MY145111A (en)	2011-12-30
ECSP088165A (es)	2008-03-26
IL188915A0 (en)	2008-04-13
WO2007021666A2 (en)	2007-02-22
JP5068755B2 (ja)	2012-11-07
RU2428180C2 (ru)	2011-09-10
WO2007021666A3 (en)	2007-05-31
AU2006280138B2 (en)	2010-03-04
EP1915130B1 (en)	2016-07-13
MX2008001967A (es)	2008-03-26
US20150080347A9 (en)	2015-03-19
NZ593121A (en)	2012-09-28
TNSN08061A1 (en)	2009-07-14
AU2006280138A1 (en)	2007-02-22
EP1915130A2 (en)	2008-04-30
BRPI0615009A2 (pt)	2011-05-03
CN101237852A (zh)	2008-08-06
GT200600350A (es)	2007-03-28
RU2011106364A (ru)	2012-08-27
NZ565696A (en)	2011-06-30
US20140179636A1 (en)	2014-06-26
HK1123188A1 (en)	2009-06-12
TWI317289B (en)	2009-11-21
CA2618018C (en)	2016-05-31
US20120328664A1 (en)	2012-12-27
CA2618018A1 (en)	2007-02-22
US20080194526A1 (en)	2008-08-14
KR20080035608A (ko)	2008-04-23
AR056020A1 (es)	2007-09-12
TW200738277A (en)	2007-10-16
KR101473494B1 (ko)	2014-12-16
US20160030572A1 (en)	2016-02-04
RU2470631C2 (ru)	2012-12-27
JP2009504653A (ja)	2009-02-05
RU2008108887A (ru)	2009-09-20
MA29736B1 (fr)	2008-09-01
PE20070337A1 (es)	2007-04-18
CN101237852B (zh)	2011-01-26
NO20081218L (no)	2008-04-29
PE20100149A1 (es)	2010-03-24

Publication	Publication Date	Title
ZA200800640B (en)	2008-12-31	Liquid formulations
GB2424581B (en)	2007-10-10	Formulations
HUE043620T2 (hu)	2019-08-28	Fenilefrin-tartalmú folyadékkészítmények
ZA200801773B (en)	2009-09-30	New formulation
EP1909584A4 (en)	2010-07-07	PRENYLFLAVONOID FORMULATIONS
TWI370115B (en)	2012-08-11	New formulation
EP2046930A4 (en)	2012-06-27	FORMULATIONS BASED ON RHAMNOLIPIDS
IL185773A0 (en)	2008-01-06	Formulations
EP1951693A4 (en)	2012-05-30	SOLID FORMULATIONS
GB0526419D0 (en)	2006-02-08	Formulation
GB0517673D0 (en)	2005-10-05	Formulation
EP1951258A4 (en)	2013-01-02	LIQUID FORMULATIONS
PL1928232T3 (pl)	2016-12-30	Stała formulacja
GB0511190D0 (en)	2005-07-06	Use
GB0520176D0 (en)	2005-11-09	Use
GB0501030D0 (en)	2005-02-23	Formulation
GB0502250D0 (en)	2005-03-09	Use
GB0526031D0 (en)	2006-02-01	Use
GB0526032D0 (en)	2006-02-01	Use
PL115561U1 (en)	2007-01-22	Spatula
GB0403769D0 (en)	2004-03-24	Liquid composition
HK1119975A (en)	2009-03-20	Liquid formulations
GB0522917D0 (en)	2005-12-21	Formulations
GB0526322D0 (en)	2006-02-01	Formulations
GB0518878D0 (en)	2005-10-26	Formulations